Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial.
Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, Kunimoto DY, Marcus DM, Wroblewski JJ, King J.
Main finding: Intravitreal Bevacizumab was non-inferior to Aflibercept in 6-month visual outcomes in macular oedema secondary to central/hemi-RVO
Purpose: To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretinal vein occlusion
Study type: Randomized controlled trial.
Condition: Central/hemi- retinal vein occlusion
Participants: ≥18 yo with macular oedema secondary to C/Hemi-RVO, ETDRS VA score 19-73, mean central subfield thickness ≥300-320 μm
n=362
Intervention:
Group 1: Intravitreal Bevacizumab 1.25mg q4weekly
Group 2: Intravitreal Aflibercept 2mg q4weekly
Mean VA letter score improvement was similar between both groups (18.6 vs 18.9); Bevacizumab was non-inferior to Aflibercept.
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive